Aquestive Therapeutics (AQST) Gross Margin (2017 - 2026)

Aquestive Therapeutics has reported Gross Margin for 10 years, with the latest figure at 70.93% in Q2 2026.

• On a quarterly basis, Gross Margin rose 1653.0% year-over-year to 70.93% in Q2 2026; TTM through Jun 2026 was 67.04%, a 594.0% increase from a year earlier, with the FY2025 full-year figure at 58.35%, down 1061.0% from the prior year.
• Gross Margin was 70.93% for Q2 2026 at Aquestive Therapeutics, down from 75.99% in the prior quarter.
• The five-year high for Gross Margin was 77.48% in Q2 2024, with the low at 50.03% in Q2 2023.
• Average Gross Margin over 5 years is 61.93%, with a median of 61.2% recorded in 2024.
• The sharpest annual moves came in 2024 and 2025: Gross Margin surged 2746 bps in 2024, then slumped 2308 bps in 2025.
• Over 5 years, Gross Margin stood at 50.34% in 2022, then climbed by 16 bps to 58.49% in 2023, then gained by 6 bps to 61.91% in 2024, then retreated by 11 bps to 55.16% in 2025, then climbed by 29 bps to 70.93% in 2026.
• The last three Gross Margin figures came in at 70.93% (Q2 2026), 75.99% (Q1 2026), and 55.16% (Q4 2025), per Business Quant data.